Heart attack patients get aggressive cholesterol drug in major new trial
NCT ID NCT04951856
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This study tests whether giving evolocumab (Repatha) injections right after a heart attack, along with standard care, helps lower 'bad' cholesterol more effectively than standard care alone. About 2,166 people who had a specific type of heart attack (STEMI or NSTEMI) and needed a stent will be randomly assigned to either evolocumab every two weeks or usual cholesterol-lowering treatment. The main goal is to see if more patients reach very low cholesterol levels and if this reduces the risk of death or unplanned heart-related hospital stays over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSTEMI - NON-ST SEGMENT ELEVATION MI are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC
Paris, 75013, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Evolocumab (Repatha), a cholesterol-lowering injection given every two weeks
What this could lead to
If successful, this could show that adding evolocumab right after a heart attack helps more people reach very low cholesterol targets and lowers the chance of dying or being hospitalized again for heart problems.
What could go wrong
This is an open-label study, so both patients and doctors know which treatment is given, which can bias results. The primary outcome is a lab measure (LDL-C), and the clinical benefit on death or hospitalization is a secondary goal. Evolocumab is already approved, so the main question is about timing and real-world effectiveness, not a breakthrough.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.